What We're Reading: Page 153
Industry reads hand-picked by our editors
May 03, 2021
-
Fortune
GoodRx helps people afford drugs. But is it improving health care or profiting off a broken system?
-
NBC News
FDA wants 'significant' amount of extra data on AstraZeneca's Covid vaccine
-
STAT
With Amgen's KRAS cancer drug, worry about pricing, not safety
-
San Diego Union-Tribune
So coronavirus vaccines aren’t perfect. They’re still very, very effective
Apr 30, 2021
-
Bloomberg
Tens of Millions of J&J Doses Sit on Shelves Awaiting FDA Review
-
Financial Times
Vaccitech valued at $579M in US public offering
-
FierceBiotech
AstraZeneca drops BCMA drug after seeing early clinical data
-
The New York Times
They Call It a 'Women’s Disease.' She Wants to Redefine It.
Apr 29, 2021
-
STAT
Biden pitches a new health agency to help 'end cancer as we know it'
-
The Washington Post
Brazil rejects Russia’s Sputnik V coronavirus vaccine in blow to Moscow’s soft power efforts
-
Investor's Business Daily
Bristol Myers Stock Slides As Earnings, Sales Fall Short
-
Philadelphia Business Journal
Pfizer puts 340-acre Collegeville campus up for sale
Apr 28, 2021
-
The New York Times
How Europe Sealed a Pfizer Vaccine Deal With Texts and Calls
-
Endpoints News
Ohana, Flagship's big bet on fertility treatments, shuts down and lays off staff after VC pulls the plug
-
STAT
A shortage of tiny pipette tips is creating huge problems for science
-
Financial Times
GSK chief defends against accusations of flat performance
Apr 27, 2021
-
The Wall Street Journal
Prescription-Drug Price Cuts Set to Be Left Out of White House Proposal
-
Associated Press
US to share AstraZeneca shots with world after safety check
-
Reuters
Top U.S. trade negotiator meets Pfizer, AstraZeneca execs on COVID-19 IP waiver
-
Evaluate Vantage
Zolgensma flatlines, but Spinraza isn't the beneficiary
Apr 26, 2021
-
Bloomberg
The First Billion Doses
-
FiercePharma
ADC Therapeutics scores FDA approval for anti-CD19 blood cancer med Zynlonta
-
The Washington Post
Vaccine maker Emergent's CEO sold $10 million in stock before company ruined Johnson & Johnson doses
-
Evaluate Vantage
Bristol's Tyk2 ticks the boxes
Apr 23, 2021
-
The New York Times
With Few New Clotting Cases, Johnson & Johnson Pause Could Be Lifted Soon
-
Life Sci VC
Five Macro Risks To Biotech Coming Out of Washington | LifeSciVC
-
The Financial Times
Scientists split over advice on giving AstraZeneca jab to UK under-40s
Previous
